Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. Viking Therapeutics and ...

PARIS, June 21, 2025 (BSS/AFP) - A new generation of weight-loss drugs has proven remarkably effective, hugely popular and ...